Ikarian Capital discloses 5.1% Kazia Therapeutics (KZIA) ADS position

Rhea-AI Filing Summary

Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G reporting a 5.1% beneficial stake in Kazia Therapeutics Limited. They report beneficial ownership of 580,754 American Depositary Shares, each ADS representing five-hundred ordinary shares of Kazia.

The ADSs may be acquired within 60 days by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts advised by Ikarian Capital. The holders state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Kazia.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Kazia Therapeutics Limited

(Name of Issuer)

American Depositary Shares, each representing five-hundred Ordinary Shares

(Title of Class of Securities)

48669G303

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 48669G303

1

Names of Reporting Persons

Ikarian Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 580,754.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 580,754.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

580,754.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent American depository shares ("American Depository Shares"), each representing five-hundred ordinary shares ("Ordinary Shares") of Kazia Therapeutics Limited (the "Issuer"), that may be acquired by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separate managed accounts, within 60 days upon the deposit of Ordinary Shares with the transfer agent. See Item 2 for more information. (2) The figure in Item 11 is based upon 11,335,991 American Depository Shares outstanding as of December 11, 2025 (assuming all outstanding Ordinary Shares were represented by American Depository Shares), as disclosed in the Issuer's Registration Statement on Form F-1, filed with the U.S. Securities and Exchange Commission (the "SEC") on December 19, 2025.

SCHEDULE 13G

CUSIP No. 48669G303

1

Names of Reporting Persons

Neil Shahrestani

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 580,754.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 580,754.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

580,754.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN, HC

Comment for Type of Reporting Person: (1) The figures in Items 6, 8, and 9 represent American Depository Shares that may be acquired by the Fund and certain separate managed accounts within 60 days upon the deposit of Ordinary Shares with the transfer agent. See Item 2 for more information. (2) The figure in Item 11 is based upon 11,335,991 American Depository Shares outstanding as of December 11, 2025 (assuming all outstanding Ordinary Shares were represented by American Depository Shares), as disclosed in the Issuer's Registration Statement on Form F-1, filed with the SEC on December 19, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Kazia Therapeutics Limited
(b)	Address of issuer's principal executive offices: Three International Towers Level 24, 300 Barangaroo Avenue, Sydney, Australia, NSW 2000
Item 2.
(a)	Name of person filing: This statement is filed jointly by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company ("Ikarian Capital"), and Neil Shahrestani (together referred herein as the "Reporting Persons"). The Fund, and certain separately managed accounts managed by Ikarian Capital (collectively, the "Managed Accounts"), are the record owners of the securities covered by this statement. Ikarian Capital is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and serves as investment manager to the Fund and as sub-adviser to the Managed Accounts, and may be deemed to have beneficial ownership of the securities covered by this statement through the investment discretion it has over the Fund and the Managed Accounts. Ikarian Capital is ultimately controlled, indirectly, by Mr. Shahrestani. Accordingly, Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by Ikarian Capital. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts. The Managed Accounts disclaim beneficial ownership of the shares held by the Fund. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of each of the Reporting Persons is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.
(c)	Citizenship: See Item 4 on the cover page(s) hereto
(d)	Title of class of securities: American Depositary Shares, each representing five-hundred Ordinary Shares
(e)	CUSIP No.: 48669G303
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover pages(s) hereto.
(b)	Percent of class: See Item 11 on the cover page(s) hereto.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page(s) hereto.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page(s) hereto.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page(s) hereto.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page(s) hereto.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The information set forth in Item 2(a) is incorporated by reference herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ikarian Capital, LLC

Signature:	/s/ Neil Shahrestani
Name/Title:	Neil Shahrestani, Sole Manager
Date:	02/17/2026

Neil Shahrestani

Signature:	/s/ Neil Shahrestani
Name/Title:	Neil Shahrestani
Date:	02/17/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement (filed herewith).

FAQ

What ownership stake in Kazia Therapeutics (KZIA) does Ikarian Capital report?

Ikarian Capital and Neil Shahrestani report beneficial ownership of 580,754 American Depositary Shares, representing 5.1% of Kazia Therapeutics’ ADS class. Each ADS corresponds to five-hundred ordinary shares, giving them a significant but minority investment position disclosed on Schedule 13G.

Who are the reporting persons on this Kazia Therapeutics (KZIA) Schedule 13G?

The Schedule 13G is filed jointly by Ikarian Capital, LLC and Neil Shahrestani. Ikarian Capital manages Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts that are the record owners of the ADSs, while Shahrestani ultimately controls Ikarian Capital indirectly.

How is beneficial ownership of Kazia Therapeutics (KZIA) ADSs structured for Ikarian Capital?

The reported ADSs may be acquired within 60 days by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts. Ikarian Capital exercises investment discretion over these vehicles, leading to deemed beneficial ownership, while the fund and managed accounts disclaim ownership of each other’s holdings.

On what share count is Ikarian’s 5.1% Kazia Therapeutics (KZIA) stake based?

The 5.1% figure is calculated using 11,335,991 American Depositary Shares outstanding as of December 11, 2025. That outstanding ADS number comes from Kazia Therapeutics’ Registration Statement on Form F-1 filed with the U.S. Securities and Exchange Commission on December 19, 2025.

Does Ikarian Capital seek control of Kazia Therapeutics (KZIA) with this stake?

The filers state the securities were acquired and are held in the ordinary course of business. They certify the holdings are not for the purpose, or with the effect, of changing or influencing the control of Kazia Therapeutics, consistent with a passive Schedule 13G filing.